Details for Patent: 9,474,752

Which drugs does patent 9,474,752 protect, and when does it expire?

Patent 9,474,752 protects LETAIRIS and is included in one NDA.

This patent has sixteen patent family members in fourteen countries.

Summary for Patent: 9,474,752

Title:	Method for treating a pulmonary hypertension condition
Abstract:	A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
Inventor(s):	Gerber; Michael J. (Denver, CO), Dufton; Christopher (Nederland, CO)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	14/182,208
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,474,752
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 9,474,752

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead	LETAIRIS	ambrisentan	TABLET;ORAL	022081-001	Jun 15, 2007	AB	RX	Yes	No						FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL
Gilead	LETAIRIS	ambrisentan	TABLET;ORAL	022081-002	Jun 15, 2007	AB	RX	Yes	Yes						FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL

International Family Members for US Patent 9,474,752

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007333115
Canada	2669536
Cyprus	1116597
Denmark	2101777